Dan O’Shannessy, Ph.D.

Dan O’Shannessy, Ph.D.

Daniel J. O'Shannessy, Ph.D. has over 18 years experience in a combination of scientific, business development and strategic planning roles within the life sciences industry. In recent years Dr. O'Shannessy has held the positions of Chief Operating Officer of Targeted Diagnostics & Therapeutics, Inc. (TDT, West Chester, PA), Senior Director of Strategic Planning, Oncology Diagnostics at Gen-Probe, Inc. of San Diego, California, and Chief Scientific Officer at Fujirebio Diagnostics, Inc. (FDI, Malvern, PA).

Randy Nelson, Ph.D.

Randy Nelson, Ph.D.

Dr. Nelson directs the Molecular Biomarkers Laboratory (MBL) at the Biodesign Institute at Arizona State University, and also holds the positions of Research Professor in the Biodesign and Affiliate Professor in the Dept. of Chemistry & Biochemistry. The Mission of the MBL is to “Improve human health through the greater understanding of protein behavior in healthy and disease populations”.

Robert Mittman, M.S., M.P.P.

Robert Mittman, M.S., M.P.P.

As founder of Facilitation, Foresight, Strategy, Robert Mittman works with groups of organizations to discover and implement shared approaches to complex and intractable problems. He engages audiences in a lively exchange of perspectives to turn simple meetings into forums that allow diverse individuals to work productively together.

Elizabeth Mansfield, Ph.D.

Elizabeth Mansfield, Ph.D.

Dr. Mansfield is the Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices and Radiological Health (OIR) in the Center for Devices, FDA, where she is developing a program to address companion and novel diagnostic devices.  Dr. Mansfield formerly served as the Director of Regulatory Affairs at Affymetrix, Inc, 2004-2006.  Dr. Mansfield received her Ph.D. from Johns Hopkins University. 

David Mallery, JD, MBA

David Mallery, JD, MBA

David Mallery, J.D., MBA is a co-founder and the President of Viomics, Inc., the International Genomics Consortium (IGC) and Paradigm Diagnostics, and was formerly the founder of the Molecular Profiling Institute (MPI) and was the President of Caris MPI following the successful acquisition. Viomics has discovered and is finalizing exceptionally accurate blood RNA markers for a variety of cancers.  IGC is instrumental for the biospecimen accrual, amplification, and processing aspects of The Cancer Genome Atlas project for the National Cancer Institute.

Carlo Maley, Ph.D.

Carlo Maley, Ph.D.

Carlo Maley is the director of the Center of Evolution and Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He is also an associate professor in the Surgery Department at UCSF and part of the Seattle Barrett’s Esophagus Research Program. He received a M.Sc. degree from the University of Oxford, studying evolutionary biology with W.D. Hamilton. He earned his Ph.D.

Joshua LaBaer, MD, Ph.D.

Joshua LaBaer, MD, Ph.D.

Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized medicine. His efforts involve the discovery and validation of biomarkers — unique molecular fingerprints of disease — which can provide early warning for those at risk of major illnesses, including cancer and diabetes.

Peter Kuhn, Ph.D.

Peter Kuhn, Ph.D.

Dr. Kuhn is a scientist and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care.

Dr. Kuhn is the Dean’s Professor of Convergent Science at USC, a co-founder of the BRIDGE @ USC and director of the Southern California Physics Oncology Center. His research is shedding new light at how cancer spreads through the body. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. 

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS